Because women with BRCA1 and BRCA2 mutations are already at high risk of developing breast and ovarian cancers, the combined effects of risk-modifying variants could lead to much larger differences in the absolute risk of developing the disease as compared with the general population (12,13,15,16). The gene discussed is BRCA1; the disease is ovarian carcinoma.